Brief: Abbisko Cayman Says Unit Granted Therapy Designation By Center For Drug Evaluation Of NMPA
20/07/2022 02:13
July 20 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* UNIT HAS BEEN GRANTED THERAPY DESIGNATION BY CENTER FOR
DRUG
EVALUATION OF NMPA FOR TREATMENT OF TENOSYNOVIAL GIANT CELL
TUMOR
Source text for Eikon: ID:nHKS5MLjtW
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Medicine
See all newsChina's Abbisko jumps on positive clinical trial results for achondroplasia drug
Brief: Abbisko Cayman Says Unit Completes First Patient Dosing In Phase I Trial Of ABSK211
Brief: Abbisko Cayman Gets IND Clearance From FDA For Oral Small Molecule Pan-Kras Inhibitor ABSK211
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration